BATF or JUN mediated enhanced leukemia clearance in our model independent of starting cell state, indicating that these TFs may derive most of their early in vivo activity via binding to NFAT-AP1 composite motifs, which show high accessibility in both cell types. The gene discussed is JUN; the disease is leukemia.